An introduction is presented in which the editor discusses various reports within the issue on topics including human immunodeficiency virus (HIV) treatment in the U.S., antiretroviral therapy (ART), and cost effectiveness of drugs including 2-drug dolutegravir (DTG) and lamivudine (3TC).